Collegium Pharmaceutical, which is developing an abuse-deterrent oral formulation of oxycodone for pain, raised $70 million by offering 5.8 million shares at $12, the low end of the range of $12 to $14. Collegium Pharmaceutical plans to list on the NASDAQ under the symbol COLL. Collegium Pharmaceutical initially filed confidentially on 3/3/2015. Jefferies & Co. and Piper Jaffray acted as lead managers on the deal.
